RT Journal Article
SR Electronic
T1 Low coverage whole genome sequencing of low-grade dysplasia strongly predicts colorectal cancer risk in ulcerative colitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.08.24309811
DO 10.1101/2024.07.08.24309811
A1 Bakir, Ibrahim Al
A1 Curtius, Kit
A1 Cresswell, George D
A1 Grant, Heather E
A1 Nasreddin, Nadia
A1 Smith, Kane
A1 Nowinski, Salpie
A1 Guo, Qingli
A1 Belnoue-Davis, Hayley L
A1 Fisher, Jennifer
A1 Clarke, Theo
A1 Kimberley, Christopher
A1 Mossner, Maximilian
A1 Dunne, Philip D
A1 Loughrey, Maurice B
A1 Speight, Ally
A1 East, James E
A1 Wright, Nicholas A
A1 Rodriguez-Justo, Manuel
A1 Jansen, Marnix
A1 Moorghen, Morgan
A1 Baker, Ann-Marie
A1 Leedham, Simon J
A1 Hart, Ailsa L
A1 Graham, Trevor A
YR 2024
UL http://medrxiv.org/content/early/2024/07/08/2024.07.08.24309811.abstract
AB Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC), and this risk increases dramatically in those who develop low-grade dysplasia (LGD). However, there is currently no accurate way to risk-stratify patients with LGD, leading to both over- and under-treatment of cancer risk. Here we show that the burden of somatic copy number alterations (CNAs) within resected LGD lesions strongly predicts future cancer development. We performed a retrospective multi-centre validated case-control study of n=122 patients (40 progressors, 82 non-progressors, 270 LGD regions). Low coverage whole genome sequencing revealed CNA burden was significantly higher in progressors than non-progressors (p=2x10-6 in discovery cohort) and was a very significant predictor of CRC risk in univariate analysis (odds ratio = 36; p=9x10-7), outperforming existing clinical risk factors such as lesion size, shape and focality. Optimal risk prediction was achieved with a multivariate model combining CNA burden with the known clinical risk factor of incomplete LGD resection. The measurement of CNAs in LGD lesions is a robust, low-cost and rapidly translatable predictor of CRC risk in IBD that can be used to direct management and so prevent CRC in high-risk individuals whilst sparing those at low-risk from unnecessary intervention.Competing Interest StatementThe authors are in discussions about potential commercialisation and clinical translation of the findings described here. Professor Hart has served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Galapogos, Lilly, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Roche, Shire and Takeda. K Curtius has an investigator-led research grant from Phathom Pharmaceuticals.Funding StatementThe study was principally funded by Cancer Research UK (Early Detection project award 25901) to TA Graham and SJ Leedham, and the Barts Charity (large project grant 472-2300) to TA Graham. We acknowledge a contribution from Bowel Research UK to TA Graham via their PhD student funding scheme, and pilot funding from the 40tude charity to TA Graham and AL Hart. TA Graham received additional funding from Cancer Research UK (CRUK A19771 and DRCNPG-May21_100001). SJ Leedham was supported by CRUK Program Grant (DRCNPG-Jun22\100002). I Al Bakir was funded by an MRC clinical studentship. Support for this research was provided by the NIHR Imperial BRC. NA Wright received funding from Cancer Research UK Program Grant A2187. M Jansen is supported by a Cancer Research UK Clinician Scientist Fellowship (A22745). K Curtius received funding from an MRC HDR-UK programme (UKRI Rutherford Fund Fellowship). This work was supported by AGA Research Foundation (AGA Research Scholar Award AGA2022-13-05; K Curtius) and NIH grants (R01 CA270235, P30 CA023100; K Curtius). This work was supported in part by a Merit Review Award I01 BX005958 (K Curtius) from the United States (U.S.) Department of Veterans Affairs Biomedical Laboratory Research and Development Service. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. The study was supported in part by the NIDDK-funded San Diego Digestive Diseases Research Center (P30 DK120515). JE East is funded by the National Institute for Health Research Oxford Biomedical Research Centre. The views expressed are those of the author and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Committee (REC) of NHS England (Fulham office) gave ethical approval for this work (NHS REC reference 18/LO/2051).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes